BG106851A - Calcium dicarboxylate ethers, methods of making same, and their use for the treatment of vascular disease and diabetes therewith - Google Patents

Calcium dicarboxylate ethers, methods of making same, and their use for the treatment of vascular disease and diabetes therewith

Info

Publication number
BG106851A
BG106851A BG106851A BG10685102A BG106851A BG 106851 A BG106851 A BG 106851A BG 106851 A BG106851 A BG 106851A BG 10685102 A BG10685102 A BG 10685102A BG 106851 A BG106851 A BG 106851A
Authority
BG
Bulgaria
Prior art keywords
treatment
methods
vascular disease
making same
diabetes
Prior art date
Application number
BG106851A
Other languages
Bulgarian (bg)
English (en)
Inventor
Howard ANDO
Donald BUTLER
Gary DOZEMAN
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of BG106851A publication Critical patent/BG106851A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/125—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/305—Saturated compounds containing more than one carboxyl group containing ether groups, groups, groups, or groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
BG106851A 2000-01-25 2002-06-20 Calcium dicarboxylate ethers, methods of making same, and their use for the treatment of vascular disease and diabetes therewith BG106851A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17782300P 2000-01-25 2000-01-25
PCT/IB2001/000026 WO2001055078A1 (en) 2000-01-25 2001-01-11 Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith

Publications (1)

Publication Number Publication Date
BG106851A true BG106851A (en) 2003-01-31

Family

ID=22650106

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106851A BG106851A (en) 2000-01-25 2002-06-20 Calcium dicarboxylate ethers, methods of making same, and their use for the treatment of vascular disease and diabetes therewith

Country Status (39)

Country Link
EP (1) EP1259474B1 (sr)
JP (1) JP4750995B2 (sr)
KR (1) KR20020073182A (sr)
CN (1) CN1395555A (sr)
AP (1) AP2002002587A0 (sr)
AR (1) AR029436A1 (sr)
AT (1) ATE431326T1 (sr)
AU (1) AU2214001A (sr)
BG (1) BG106851A (sr)
BR (1) BR0107763A (sr)
CA (1) CA2397960C (sr)
CO (1) CO5261537A1 (sr)
CZ (1) CZ20022474A3 (sr)
DE (1) DE60138686D1 (sr)
DK (1) DK1259474T3 (sr)
DZ (1) DZ3239A1 (sr)
EA (1) EA004862B1 (sr)
EE (1) EE200200404A (sr)
ES (1) ES2324281T3 (sr)
GE (1) GEP20053428B (sr)
GT (1) GT200100015A (sr)
HN (1) HN2001000011A (sr)
HU (1) HUP0204422A3 (sr)
IL (1) IL150541A0 (sr)
IS (1) IS6442A (sr)
MA (1) MA26867A1 (sr)
MX (1) MXPA02007223A (sr)
NO (1) NO20023526L (sr)
NZ (1) NZ519550A (sr)
OA (1) OA12166A (sr)
PA (1) PA8510601A1 (sr)
PE (1) PE20011064A1 (sr)
PL (1) PL357076A1 (sr)
SK (1) SK10622002A3 (sr)
SV (1) SV2002000290A (sr)
TN (1) TNSN01013A1 (sr)
UY (1) UY26550A1 (sr)
WO (1) WO2001055078A1 (sr)
ZA (1) ZA200205880B (sr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1481962A1 (en) * 1997-12-12 2004-12-01 Warner-Lambert Company LLC New cholesterolemia-lowering carboxyalkylether compound
PL375742A1 (en) * 2002-08-22 2005-12-12 Warner-Lambert Company Llc Method of treating osteoarthritis
US7816405B2 (en) 2005-04-19 2010-10-19 Eisai R&D Management Co., Ltd. Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof
EP1873141A4 (en) * 2005-04-19 2010-09-22 Eisai R&D Man Co Ltd CALCIUM-BIS [2S] -3- [3- (2S) -3- (4-CHLORO-2-CYANOPHENOXY) -2-FLUORO-PROPOXYPHENYL] -2-ISOPROPOXYPROPIONATE] AND INTERMEDIATE PRODUCTS THEREOF
AU2015346037A1 (en) * 2014-11-14 2017-07-06 Gemphire Therapeutics Inc. Processes and intermediates for preparing alpha,omega-dicarboxylic acid-terminated dialkane ethers
CN110996928A (zh) * 2017-04-18 2020-04-10 燿石治疗公司 吉卡宾、其药学上可接受的盐、其组合物和其使用方法
US20200253877A1 (en) * 2018-10-18 2020-08-13 Neurobo Pharmaceuticals, Inc. Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
NZ503982A (en) 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus

Also Published As

Publication number Publication date
PE20011064A1 (es) 2001-10-22
IS6442A (is) 2002-06-25
NO20023526L (no) 2002-08-27
SK10622002A3 (sk) 2003-07-01
ZA200205880B (en) 2003-07-23
OA12166A (en) 2003-11-07
CA2397960A1 (en) 2001-08-02
DE60138686D1 (de) 2009-06-25
MA26867A1 (fr) 2004-12-20
KR20020073182A (ko) 2002-09-19
EA200200641A1 (ru) 2002-12-26
AP2002002587A0 (en) 2002-09-30
MXPA02007223A (es) 2002-11-29
CA2397960C (en) 2008-09-09
JP2003520835A (ja) 2003-07-08
CN1395555A (zh) 2003-02-05
AU2214001A (en) 2001-08-07
EA004862B1 (ru) 2004-08-26
NO20023526D0 (no) 2002-07-24
PA8510601A1 (es) 2002-08-26
EP1259474A1 (en) 2002-11-27
HUP0204422A2 (en) 2003-05-28
EE200200404A (et) 2003-10-15
DZ3239A1 (fr) 2001-08-02
CZ20022474A3 (cs) 2003-06-18
WO2001055078A1 (en) 2001-08-02
GT200100015A (es) 2001-10-19
AR029436A1 (es) 2003-06-25
HUP0204422A3 (en) 2003-08-28
JP4750995B2 (ja) 2011-08-17
NZ519550A (en) 2003-11-28
ATE431326T1 (de) 2009-05-15
UY26550A1 (es) 2001-08-27
EP1259474B1 (en) 2009-05-13
ES2324281T3 (es) 2009-08-04
IL150541A0 (en) 2003-02-12
BR0107763A (pt) 2002-11-12
DK1259474T3 (da) 2009-07-20
CO5261537A1 (es) 2003-03-31
TNSN01013A1 (fr) 2005-11-10
SV2002000290A (es) 2002-07-16
PL357076A1 (en) 2004-07-12
GEP20053428B (en) 2005-01-25
HN2001000011A (es) 2001-06-13

Similar Documents

Publication Publication Date Title
DE50102490D1 (de) Verwendung von substituierten imidazo [1,2-a]pyridin-, -pyrimidin- und -pyrazin-3-yl-amin-derivaten zur herstellung von medikamenten zur nos-inhibierung
WO2000061568A3 (de) Mit zuckerresten substituierte 1,4-benzothiazepin-1,1-dioxidderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
DE69522947D1 (en) Phenylxanthin-derivate
PT711282E (pt) Compostos inibidores de pde iv e de fnt
JO2493B1 (en) New phenyl azatidinone with improved physical properties and methods of preparation of drugs containing it and its uses
WO2005016261A3 (en) Aripiprazole and haloperidol pamoate salts
PL1725536T3 (pl) Pochodne imidazoliny mające czynność CB1-antagonistyczną
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
PE20010402A1 (es) Derivados de 1,5-dihidropirrol-2-ona sustituida
ES2187261A1 (es) Compuestos de eteres y amidas y su preparacion, como agentes anti-diabeticos.
BG106851A (en) Calcium dicarboxylate ethers, methods of making same, and their use for the treatment of vascular disease and diabetes therewith
MY128241A (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
IL153561A0 (en) 4-alkoxy cyclohexane-1-amino carboxylic acid esters and method for the production thereof
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
PL344056A1 (en) Piperididinyl and n-amidinopiperidinyl derivatives
IL165220A0 (en) Novel compounds, their use and preparation
BRPI0417179A (pt) gentisato de amlodipina, método de preparar o mesmo e composição farmacêutica para tratamento de doenças cardiovasculares
BR0306701A (pt) Composto, sal do composto, sal de cálcio, método de preparação de um sal, composição farmacêutica, método de preparação de uma composição, e, uso de um sal
WO2006074919A3 (de) 3 -AMINO- 6-ARYL (BZW.6-HETEROARYL) -THIENO [2 , 3-B] PYRIDIN-2-CARBONSÄUREAMIDE, DIESE ENTHALTENDE PHARMAZEUTISCHE ZUBEREITUNGEN UND IHRE VERWENDUNG ALS INHIBITOREN DER TNFα-FREISETZUNG
IL166103A0 (en) Pyrrolidine derivatives and their use
MXPA05012743A (es) Composicion de limpieza mejorada.
DE69930621D1 (de) Medizinische zusammensetzungen zur unmittelbaren freisetzung bei oraler anwendung
EA199900675A2 (ru) Полиморф моногидрата зополрестата
IL149544A0 (en) N-ACYLPYRROLIDIN-2-YLALKYLBENZAMIDINE DERIVATIVES AS INHIBITORS OF FACTOR Xa
SG146685A1 (en) Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them